AMSH divests Her Option to CooperSurgical for $20.5mm

Deal summary reprinted from Strategic Transactions - February, 2010

Just months after selling off its Ovion Eclipse female sterilization assets to Conceptus, American Medical Systems Holdings (gynecological and urological devices) has now divested its Her Option global endometrial ablation product line to CooperSurgical (gynecological devices) for $20.5mm in cash. Read more...

Deal summary reprinted from Strategic Transactions - February, 2010

The Her Option products brought in $10mm in revenues over the last 12 months. The treatment, a cryoblation therapy that can be performed in an ob/gyn's office under minimal anesthesia and with little discomfort, was approved by the FDA in 2001 for women with excessive menstrual bleeding that do not want to have a hysterectomy. AMSH purchased its developer, CryoGen, in 2002, but is divesting Her Option--which it calls a non-strategic asset--in order to focus on selling its products for men (urinary incontinence and erectile dysfunction) and women (urinary and fecal incontinence and vaginal prolapse) in the pelvic health markets.

Find out more about what our Strategic Transactions - The Device Deal Database can do for you.

Strategic Transactions - The Device Deal Database provides expanded information, including:

- Comprehensive Deal Records
- Complete Financial Information
- Extensive Company Profiles
- Access to important SEC Documents
- Links to related articles

Contact: James DeFalco at: +1 (203) 838-4401 x104 or [email protected]